Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

The National Committee To Preserve Social Security And Medicare - Protecting The Health And Economic Future Of Older Americans
"As the President himself has said, America does not face an entitlement
generic viagra online
Society Of Gynecologic Oncologists Issues White Paper On HPV Vaccine's Impact On Cervical Cancer Prevention
The Society of Gynecologic Oncologists (SGO) has published the first in a series of four papers on a variety of cervical cancer issues and topics that were the focus of its Forum "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare," held last September in Chicago, Illinois. The paper, entitled "The Impact of Human Papillomavirus Vaccination on Cervical Cancer Prevention Efforts," is featured in the August, 2009 issue of Gynecologic Oncology. It includes data relevant to HPV natural history as well as excerpts from Forum discussions regarding the limits of current screening, the impact that eliminating HPV 16/18 through vaccination may have on rates of cervical precancer and cervical cancer screening, strategies to measure vaccine uptake and obstacles surrounding separate screening for vaccinated women.
plastic surgery before after
News of the day
PanGenetics Receives Approval For Clinical Evaluation Of Anti-NGF Antibody In Patients With Chronic Pain
PanGenetics B.V. announced that the Competent Authority of the Netherlands has approved the Clinical Trials Application for a first-in-man study with antibody PG110. This humanized antibody is a member of the class of Nerve Growth Factor (NGF) inhibitors which represent a promising novel approach in the treatment of chronic pain. PG110 will be evaluated in patients suffering from pain caused by osteoarthritis (OA). The clinical trial is designed as a double blind, placebo controlled study and will be conducted in a single site in Utrecht, the Netherlands, in collaboration with Kendle International.
Nutrition

UCB And PatientsLikeMe Partner To Give People With Epilepsy A Voice In Advancing Research

Biopharma company UCB and PatientsLikeMe, the leading online community for people with life-changing conditions, today announced a strategic partnership to create an online, open epilepsy community that captures real-world experiences of people living with epilepsy in the U.S. Scheduled to launch in early 2010, this platform will be designed to collect, analyze and reflect information received from people with epilepsy, regardless of their diagnosis, prognosis or treatment regimen. "UCB has a longstanding commitment to improving the lives of people living with severe conditions," said Roch Doliveux, Chief Executive Officer, UCB. "This partnership is exciting because for the first time, patients will be able to contribute their experiences and real-world data to ongoing epilepsy research." UCB is the first pharmaceutical company to partner with PatientsLikeMe to launch a patient community. The new epilepsy community will help create a platform for people with epilepsy that will enable UCB to better understand patients, their lives and treatment experiences. Participants will record their real-time day-to-day progress in controlling their seizures and achieving their treatment goals, and share that with the community to help patients, caregivers, researchers and industry learn more about the disease. "What we"re seeing on our site every day is that patients are interested in learning more about their disease" says Ben Heywood, President and Co-founder of PatientsLikeMe. "By joining forces with industry leaders like UCB, we can turn up the volume of the patient voice in companies who are committed to hearing it and working toward better treatments and better care." Epilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and between 2.5 and 3 million Americans.[1], [2] An often stigmatized and misunderstood condition, epilepsy can strike anyone at any time, but new cases are most common among young children and older adults. The number of people living with epilepsy in the U.S. is expected to rise as the population ages.[1] There is no cure for epilepsy, though treatments have improved in the last ten to twenty years.[3] References [1.] Epilepsy Foundation. Epilepsy: Just the Facts. March 2008. Accessed here. [2.] U.S. Centers for Disease Control and Prevention. Epilepsy Fast Facts. March 2009. Accessed here. UCB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009